Allogene Executives Sell Shares Amid Market Volatility

Allogene Therapeutics, Inc. announced on February 2, 2026, that its Senior Vice President and Chief Technical Officer, Benjamin Machinas, sold 7,549 shares at a price of $1.73 per share. The company's Director, President, and CEO, David D. Chang, sold 95,269 shares at a price of $1.8 per share on the same day. Additionally, the Senior Vice President, General Counsel, Douglas Earl Martin, sold 22,900 shares at a price of $1.76 per share, while the Chief Financial Officer, Geoffrey M. Parker, sold 24,001 shares at a price of $1.76 per share. The EVP of R&D, Zachary Roberts, sold 35,700 shares at a price of $1.77 per share, and the SVP of Finance, Annie Yoshiyama, sold 4,167 shares at a price of $1.72 per share.